Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: Potential implications for breast cancer therapy

International Journal of Cancer

Volumn 103, Issue 5, 2003, Pages 600-605

  Winnett, Georgia ^a   Van Hagen, Daphne ^a   Schrey, Michael ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Aromatase; Breast cancer; PGJ2 metabolites

Indexed keywords

15 DEOXY DELTA 12,14 PROSTAGLANDIN J2; 4 CYCLOPENTENE 1,3 DIONE; 9 DEOXY DELTA 9,12 13,14 DIHYDRO PROSTAGLANDIN D2; ACETYLCYSTEINE; ARACHIDONIC ACID; AROMATASE; CYCLOPENTENONE DERIVATIVE; HYDROGEN PEROXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN J2; UNCLASSIFIED DRUG; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; ANTIOXIDANT; AROMATASE INHIBITOR; CELL RECEPTOR; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUTATHIONE; PROSTAGLANDIN D2; THIOL REAGENT; TRANSCRIPTION FACTOR;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME MODIFICATION; HUMAN; HUMAN CELL; OXIDATION; PRIORITY JOURNAL; REDUCTION; STRUCTURE ACTIVITY RELATION; BREAST; BREAST TUMOR; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; FEMALE; FIBROBLAST; METABOLISM; OXIDATION REDUCTION REACTION;

ACETYLCYSTEINE; ANTIOXIDANTS; AROMATASE; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FIBROBLASTS; GLUTATHIONE; HUMANS; HYDROGEN PEROXIDE; OXIDATION-REDUCTION; PROSTAGLANDIN D2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFHYDRYL REAGENTS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0037455655     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10878     Document Type: Article

References (26)

1. 2 exerting cell growth inhibition. Biochem Biophys Res Commun 1985;127:739-45.
2. 2 induce apoptosis in L1210 cells. FEBS Lett 1993;321:209-14.
3. 2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation. Cancer Res 1996;56:3866-9.
4. Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA, Chilton FH. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999;20:1905-11.
5. Bui T, Straus DA. Effects of cyclopentenone prostaglandins and related compounds on insulin-like growth factor-I and Waf1 gene expression. Biochem Biophys Acta 1998;1397:31-42.
6. Narumiya S, Fukushima M. Site and mechanisms of growth inhibition by prostaglandins. I. Active transport and intracellular accumulation of cyclopentenone prostaglandins, a reaction leading to growth inhibition. J Pharmacol Exp Ther 1986;239:500-5.
7. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
8. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60:1604-8.
9. Santen RJ, Martel J, Hoagland F, Naftolin F, Roa L, Harada N, Hafer L, Zaino R, Santner SJ. Stromal spindle cells contain aromatase in human breast tumors. J Clin Endocrinol Metab 1994;79:627-32.
10. Miller WR. Aromatase inhibitors and breast cancer. Cancer Treat Rev 1997;23:171-87.
11. Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole in postmenopausal patients with breast cancer. Clin Cancer Res 1995;2:1511-5.
12. Brodie A, Lu Q, Liu Y, Long B. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 1999;6:205-10.
13. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR. Aromatase expression in health and disease. Recent Prog Horm Res 1997;52:185-214.
14. 2. Endocr Relat Cancer 1999;6:139-47.
15. 2 metabolites inhibit aromatase activity in breast cancer cells: evidence of a role for cellular redox status. J Endocrinol 2000;164(Suppl):P286.
16. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB Kinase. Nature 2000;403:103-8.
17. Wilmer WA, Dixon C, Lu L, Hilbelink T, Rovin BH. A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARγ. Biochem Biophys Res Comm 2001;281:57-62.
18. 2. Prostaglandins 1996;51:413-25.
19. 2 receptors in the respective control of cell growth and phospholipid hydrolysis. Cancer Res 1992;52:334-40.
20. 2 in the autocrine control of cell function. Int J Cancer 1996;67:684-9.
21. Honn KV, Marnett LJ. Requirement of a reactive α,β-unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by "A" series prostaglandins. Biochem Biophys Res Commun 1985;129:34-40.
22. 2 with intracellular glutathione and enhancement of its antiproliferative activity by glutathione depletion. Cancer Res 1990;50:1879-85.
23. Shatrov AV, Ameyar M, Bouquet C, Cai Z, Stancou R, Haddada H, Chouaib S. Adenovirus-mediated wild-type-p53 gene expression sensitizes TNF-resistant tumor cells to TNF-induced cytotoxicity by altering the cellular redox state. Int J Cancer 2000;85:93-7.
24. 2, a ligand for peroxisome proliferator-activated receptor gamma, induces apoptosis in JEG-3 choriocarcinoma cells. Biochem Biophys Res Comm 1999;262:579-85.
25. Snyder GD, Holmes RW, Bates JN, Van-Voorhis BJ. Nitric oxide inhibits aromatase activity: mechanisms of action. J Steroid Biochem Mol Biol 1996;58:63-9.
26. 2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 1995;72:1412-9.